significant new advance to prevent serious respiratory syncytial virus (RSV) infections in young children
November 1998
There's a significant new advance to prevent serious respiratory syncytial virus (RSV) infections in young children.
It's called Synagis (palivizumab)...for preemies and young children with lung disease who are at risk for pulmonary RSV infections.
Synagis is a monoclonal antibody. It binds to a protein on the surface of the virus to prevent it from infecting cells.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote